Ahmad Nanaa

9PUBLICATIONS
26CO-AUTHORS
Gene and molecular therapyMedical infection agents (incl. prions)Haematological tumoursPredictive and prognostic markersMedical biochemistry - proteins and peptides (incl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Feb 20, 2024
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Talha Badar, Ahmad Nanaa, Ehab Atallah

|Sep 22, 2023
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.

Talha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa

|Sep 15, 2023
Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.

Ahmad Nanaa, Rong He, James M Foran

|Apr 09, 2023
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.

Aref Al-Kali, Ahmad Nanaa, David Viswanatha

|Dec 08, 2022
Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience.

Bahga Katamesh, Ahmad Nanaa, Rong He

|Jul 08, 2022
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.

Mithun Vinod Shah, Abhishek A Mangaonkar, Kebede H Begna

Pageof 2

Frequent Collaborators

7 joint publications

Rong He

6 joint publications

Talha Badar

6 joint publications

Aref Al-Kali

6 joint publications

Naseema Gangat